Sinus Decongestant Nasal Tablets Recalled for cGMP Deviations
Ultra Seal Corporation is recalling 448,300 packets of SINUS DECONGESTANT (phenylephrine HCl 5mg) tablets due to current Good Manufacturing Practice (cGMP) deviations. The recall affects nationwide distribution.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall initiated voluntarily by the firm for cGMP deviations. The source text does not report any illnesses, injuries, or specific health hazards—only manufacturing practice violations. Per the rubric, manufacturing/compliance issues without reported harm are typically classified as Moderate.
Plain-English summary
Ultra Seal Corporation is voluntarily recalling SINUS DECONGESTANT Nasal Decongestant tablets containing phenylephrine HCl 5mg in 2-count packets distributed by Honeywell Safety Products USA. The recall involves 448,300 packets distributed nationwide within the United States.
The recall was initiated due to cGMP (current Good Manufacturing Practice) deviations. Lot #AK9859 with an expiration date of 10/2022 is affected.
Consumers who have purchased this product should stop use. More information is available from the FDA or by contacting the recalling firm, Ultra Seal Corporation. This is a Class II recall that was terminated on October 16, 2023.
The recalled product
- Product
- SINUS DECONGESTANT Nasal Decongestant (phenylephrine HCl 5mg) tablets, 2-count packets, Dist. by Honeywell Safety Products USA, Smithfield, RI 02917
- Manufacturer
- Ultra Seal Corporation
- Category
- Drug — Nasal Decongestant
- Hazard
- cgmp-deviation
- manufacturing-compliance
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: AK9859
- Exp. Date 10/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27